These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 29627891)

  • 21. Anabolic Therapy for the Treatment of Osteoporosis in Childhood.
    Ward LM; Rauch F
    Curr Osteoporos Rep; 2018 Jun; 16(3):269-276. PubMed ID: 29589203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window.
    Bilezikian JP
    Curr Osteoporos Rep; 2008 Mar; 6(1):24-30. PubMed ID: 18430397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intermittent administration of teriparatide enhances graft bone healing and accelerates spinal fusion in rats with glucocorticoid-induced osteoporosis.
    Sugiura T; Kashii M; Matsuo Y; Morimoto T; Honda H; Kaito T; Iwasaki M; Yoshikawa H
    Spine J; 2015 Feb; 15(2):298-306. PubMed ID: 25110274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
    Skiba K; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indications to teriparatide treatment in patients with osteoporosis.
    Rizzoli R; Kraenzlin M; Krieg MA; Mellinghoff HU; Lamy O; Lippuner K
    Swiss Med Wkly; 2011; 141():w13297. PubMed ID: 22057669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?
    Girotra M; Rubin MR; Bilezikian JP
    Treat Endocrinol; 2006; 5(6):347-58. PubMed ID: 17107220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anabolic therapies for osteoporosis.
    Uihlein AV; Leder BZ
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The bone anabolic therapy.
    Nardi A; Ventura L; Cozzi L; Tonini G; Zennaro R; Celi M; Ramazzina E
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S121-4. PubMed ID: 24078441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orthopedic uses of teriparatide.
    Bukata SV; Puzas JE
    Curr Osteoporos Rep; 2010 Mar; 8(1):28-33. PubMed ID: 20425088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New anabolic therapies for osteoporosis.
    Minisola S; Cipriani C; Occhiuto M; Pepe J
    Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol.
    Jeon YK; Kim KM; Kim KJ; Kim IJ; Lim SK; Rhee Y
    Calcif Tissue Int; 2014 Feb; 94(2):159-68. PubMed ID: 23907724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abaloparatide Exerts Bone Anabolic Effects with Less Stimulation of Bone Resorption-Related Factors: A Comparison with Teriparatide.
    Makino A; Takagi H; Takahashi Y; Hase N; Sugiyama H; Yamana K; Kobayashi T
    Calcif Tissue Int; 2018 Sep; 103(3):289-297. PubMed ID: 29725706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
    Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
    J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].
    Fukumoto S
    Clin Calcium; 2014 Nov; 24(11):1701-5. PubMed ID: 25355155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anabolic Therapy for Osteoporosis.
    Ensrud KE; Schousboe JT
    JAMA; 2021 Jul; 326(4):350-351. PubMed ID: 34313699
    [No Abstract]   [Full Text] [Related]  

  • 36. Recommendations for the optimal use of bone forming agents in osteoporosis.
    Veronese N; Briot K; Guañabens N; Albergaria BH; Alokail M; Al-Daghri N; Bemden AB; Bruyère O; Burlet N; Cooper C; Curtis EM; Ebeling PR; Halbout P; Hesse E; Hiligsmann M; Camargos BM; Harvey NC; Perez AD; Radermecker RP; Reginster JY; Rizzoli R; Siggelkow H; Cortet B; Brandi ML
    Aging Clin Exp Res; 2024 Aug; 36(1):167. PubMed ID: 39120740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis.
    Toulis KA; Anastasilakis AD; Polyzos SA; Makras P
    Hormones (Athens); 2011; 10(3):174-95. PubMed ID: 22001129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures.
    Kim SJ; Park HS; Lee DW; Lee JW
    Injury; 2019 Jul; 50(7):1364-1370. PubMed ID: 31182230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
    Canalis E
    Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anabolic therapy for osteoporosis: parathyroid hormone.
    Cosman F
    Curr Osteoporos Rep; 2005 Dec; 3(4):143-9. PubMed ID: 16303114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.